RxDoctor Payments Data

Maureen Galdamez, PA

Physician Assistant · Pensacola, FLNPI 1164662334

Payments from drug & device makers

$2,987in general payments, 2019–2025

Across 164 payments — averaging $18.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$527
  • AbbVie$524
  • Novo Nordisk$436
  • Pfizer$366
  • AstraZeneca$323
  • Sanara Medtech Inc.$102
  • plus $709 from 15 others

What the payments were for

  • Food & beverage$2,975100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,987 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$96,476
Medicare patients
332
Services billed
1,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide133$146,195
TrulicityDulaglutide63$76,263
JardianceEmpagliflozin70$52,365
OzempicSemaglutide43$41,023
EliquisApixaban27$40,527
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$36,910
LinzessLinaclotide19$18,398
Soliqua 100-33Insulin Glargine/Lixisenatide27$16,849
JanuviaSitagliptin Phosphate16$15,048
Breo ElliptaFluticasone/Vilanterol24$12,656
MyrbetriqMirabegron12$9,306
DapagliflozinDapagliflozin Propanediol13$8,290
Omeprazole252$4,844
Gabapentin185$3,868
Atorvastatin Calcium277$3,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$527$222,458196 claims
Boehringer IngelheimJardiance$49$52,36570 claims
GSKTrelegy Ellipta, Breo Ellipta$73$49,56657 claims
Novo NordiskOzempic$436$41,02343 claims
PfizerEliquis$366$40,52727 claims
AbbVieLinzess, Synthroid$524$19,56935 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$43$16,84927 claims
MerckJanuvia$44$15,04816 claims
Astellas Pharma US IncMyrbetriq$64$9,30612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →